Brief: Medicenna Reports Results From Recurrent Glioblastoma Trial When Compared To An Eligibility-Matched Control Arm

Medicenna Therapeutics

13/01/2020 12:50

Jan 13 (Reuters) - Medicenna Therapeutics Corp  MDNA.TO :
    * MEDICENNA - REPORTS RESULTS FROM RECURRENT GLIOBLASTOMA
TRIAL
WHEN COMPARED TO AN ELIGIBILITY-MATCHED CONTROL ARM
    * MEDICENNA-FIRST COMPARISON OF DATA SHOWS A SINGLE
TREATMENT WITH
MDNA55 HAS ABILITY TO MORE THAN DOUBLE SURVIVAL RATES IN MOST
AGGRESSIVE FORM OF RGBM
    * MEDICENNA - RESULTS FROM SCA MORE ACCURATELY REFLECTS
PATIENT
POPULATION THAT WOULD HAVE BEEN ENROLLED IN A CONTROL ARM
SETTING

Source text for Eikon:  ID:nCNWFrhTVa 
Further company coverage:  MDNA.TO 

 ((Reuters.Briefs@thomsonreuters.com;))